Penile ultrasonography

Human medicines European public assessment report (EPAR): Defitelio, defibrotide, Date of authorisation: 18/10/2013, Revision: 16, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Marketing, Disease, Agency, Survival, INN, Penile ultrasonography, Hypotension, Hematopoietic stem cell transplantation, ATC, Blood, Bleeding, International, Mortality, European, Language, VOD, Record, Haematopoietic system, Haematopoiesis, European Medicines Agency, Transplant, SOS, Select, Cell, HSCT, Patient, Vein, Safety, Hepatic veno-occlusive disease, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Defitelio, defibrotide, Date of authorisation: 18/10/2013, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Defitelio, defibrotide, Date of authorisation: 18/10/2013, Revision: 16, Status: Authorised

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Retrieved on: 
Sunday, December 10, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Molecular Pharmacology, Fever, Associate, Azacitidine, Hypotension, Safety, CCR, Spacecraft, Pneumonia, ASH, University, Cytopenia, Disease, Cellular, Constipation, Fatigue, Mortality, Penile ultrasonography, Patient, IMGN, DNA, MRD, Medical Affairs Bureau, Pharmacokinetics, Peripheral edema, Flow cytometry, Capillary leak syndrome, MD, Diarrhea, Cancer, Nausea, Survival, Drug resistance, Transplant, AML, Apoptosis, MD Anderson Cancer Center, Society, ImmunoGen, Hypokalemia, Hypophosphatemia, Venetoclax, Rare-earth element, Pharmaceutical industry, Birth control, Vaccine, Medicinal plants, Research

These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

Key Points: 
  • These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
  • “The MRD negativity rates, which are indicative of a deep remission, are particularly promising in the treated patient population.
  • Response rates and MRD negativity were numerically comparable between cohorts 1 and 2, despite differences in the venetoclax schedule.
  • We look forward to continuing to expand our cohort of newly diagnosed unfit patients to inform the development path for pivekimab in AML.”
    ImmunoGen is also presenting two preclinical posters at ASH.

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Retrieved on: 
Friday, February 17, 2023
DNA, B cell, Immune reconstitution inflammatory syndrome, Secondary malignant neoplasm, Stanford University School of Medicine, Pediatrics, Inborn errors of metabolism, Blood, Stanford University, FA, Patient, Safety, Infection, DNA repair, European Society for Primary Immunodeficiencies, IEWP, Penile ultrasonography, Bone marrow failure, Research, Therapy, Infertility, Risk, Graft-versus-host disease, Toxic epidermal necrolysis, End organ damage, MDS, Haematopoietic system, Mucositis, Transplant, CD117, Fanconi anemia, Allotransplantation, Definitive, Syndrome, Pharmaceutical industry, Dentistry, Jasper

The study is a Phase 1/2 clinical trial ( NCT04784052 ) utilizing briquilimab to treat FA patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.

Key Points: 
  • The study is a Phase 1/2 clinical trial ( NCT04784052 ) utilizing briquilimab to treat FA patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.
  • In the follow-up data series presented, 100% total donor chimerism was achieved through six months for the first patient and at three months for the second patient.
  • Briquilimab was cleared by day 9 after dosing in both patients and no treatment-related adverse events or toxicities were observed.
  • It is also the only proven treatment for the bone marrow failure that occurs in a majority of patients with FA.